Recent Advances In Nanotechnology For Drug Delivery: A Comprehensive Review

Nanotechnology, the science of manipulating matter at dimensions typically below 100 nanometres, has dramatically expanded the frontiers of biomedical research. In medicine, nanotechnology enables precise control over the composition, distribution, and function of drugs at the molecular and cellular levels. Since its conceptual inception in the late 20th century, the field has undergone rapid evolution, transitioning from theoretical constructs to tangible clinical applications.¹ The advent of nanomedicine has ushered in a new era wherein therapeutic interventions are increasingly sophisticated, leveraging nanoscale engineering to address the limitations of conventional treatment modalities.²

Traditional drug delivery systems, such as oral tablets or intravenous injections, often suffer from significant drawbacks, including nonspecific biodistribution, poor solubility, rapid systemic clearance, and limited capacity to cross biological barriers. These limitations compromise drug efficacy and increase the risk of adverse effects, particularly in diseases requiring site-specific treatment such as cancer, neurodegenerative disorders, and chronic infections. Moreover, systemic toxicity and multidrug resistance continue to challenge clinicians and pharmacologists alike, highlighting the urgent need for more effective and safer delivery strategies.³

Nanotechnology offers a compelling solution to these unmet needs. The key goals of nanotechnology-based drug delivery systems include: (1) targeted delivery to specific tissues or cells, minimising off-target effects and enhancing therapeutic efficacy; (2) controlled and sustained drug release, maintaining optimal drug concentrations over time; and (3) the ability to traverse biological barriers such as the blood-brain barrier, gastrointestinal lining, and tumour microenvironment. By achieving these objectives, nanocarriers can significantly enhance pharmacokinetics and pharmacodynamics, ultimately leading to improved clinical outcomes.⁴

Various types of nanocarriers have been developed to achieve these goals. Liposomes, among the earliest and most extensively studied, offer biocompatibility and versatility in drug encapsulation. Polymeric nanoparticles allow for tunable degradation rates and controlled release profiles. Dendrimers, with their highly branched architecture, facilitate multivalent interactions and offer a high payload capacity. Solid lipid nanoparticles combine the advantages of lipids and polymers for enhanced stability and drug protection. Inorganic nanocarriers, such as gold nanoparticles and quantum dots, possess unique optical and electronic properties that enable the integration of diagnostic and therapeutic applications in modern oncology.^5,6

The scope of this review encompasses the design principles, functional attributes, and clinical applications of the most prominent nanocarriers in drug delivery. We will begin by examining the physicochemical characteristics and synthesis methods of various nanocarriers. The subsequent sections will delve into the mechanisms of drug loading and release, strategies for targeting and crossing biological barriers, and recent advances in stimuli-responsive systems. We will also highlight key translational milestones, including approved nanomedicine products and ongoing clinical trials. Finally, we will discuss prevailing challenges and potential future directions, particularly the integration of nanotechnology with emerging fields like artificial intelligence and personalised medicine.

Through this comprehensive analysis, we aim to provide an in-depth understanding of how nanotechnology is reshaping the landscape of drug delivery, bridging the gap between bench-side innovation and bedside application.

1. Classification of Nanocarriers

Nanocarriers are the cornerstone of nanotechnology-enabled drug delivery systems, enabling the transport of therapeutic agents with enhanced precision, efficacy, and safety.⁷ They can be broadly categorised based on their structural composition and physicochemical properties into lipid-based systems, polymeric nanoparticles, inorganic nanoparticles, dendrimers, micelles/nanospheres, and emerging biomimetic carriers such as exosomes. Each category brings distinct advantages and design considerations tailored to specific biomedical applications.⁸

1. Lipid-Based Systems

Liposomes: These spherical vesicles consist of one or more phospholipid bilayers surrounding an aqueous core. Their biocompatibility, ability to encapsulate both hydrophilic and lipophilic drugs, and ease of surface modification make them highly versatile. Liposomal formulations, such as Doxil (doxorubicin liposomes), are already clinically approved, demonstrating their potential for effective and safe drug delivery.⁹

Solid Lipid Nanoparticles (SLNs): Composed of solid lipids stabilised by surfactants, SLNs offer excellent physical stability, controlled drug release, and protection of labile drugs. They overcome some limitations of liposomes, such as drug leakage and fusion.¹⁰

Nanostructured Lipid Carriers (NLCs): NLCs are second-generation lipid nanoparticles comprising a blend of solid and liquid lipids. This composition results in improved drug loading capacity and reduced drug expulsion during storage. NLCs are particularly promising in dermal and transdermal delivery systems.¹¹

2. Polymeric Nanoparticles

Natural Polymers: Chitosan and gelatin are widely used due to their biodegradability, mucoadhesive properties, and minimal toxicity. Chitosan nanoparticles exhibit a strong interaction with negatively charged biological membranes, thereby enhancing cellular uptake and facilitating the opening of tight junctions for the transport of drugs.¹²

Synthetic Polymers: Polymers like PLGA (poly(lactic-co-glycolic acid)) and PEG (polyethene glycol) offer controlled degradation rates and enhanced circulation times. PLGA is FDA-approved and widely used due to its tunable mechanical and chemical properties. PEGylation of nanoparticles enhances systemic stability and evades immune recognition.¹³

3. Inorganic Nanoparticles

Inorganic nanoparticles bring unique physical and optical properties that are advantageous in drug delivery and imaging.

Gold Nanoparticles: Known for their tunable size, ease of functionalisation, and photothermal capabilities, gold nanoparticles are functional in targeted drug delivery and cancer therapy.¹⁴

Silica Nanoparticles: Mesoporous silica nanoparticles (MSNs) offer a high surface area and tunable pore sizes, facilitating efficient drug loading and controlled release.¹⁵

Iron Oxide Nanoparticles: Their superparamagnetic properties are exploited in magnetic resonance imaging (MRI) and magnetically guided drug delivery.¹⁶

Quantum Dots: These semiconductor nanocrystals possess unique fluorescent properties, making them ideal for real-time tracking of drug distribution; however, their heavy metal content raises concerns about biocompatibility.¹⁷

4. Dendrimers

Dendrimers are highly branched, monodisperse macromolecules characterised by a central core, interior branches (or generations), and multiple surface functional groups.¹⁸ Poly(amidoamine) (PAMAM) dendrimers are the most extensively studied of all dendrimers. Their multivalency allows high drug loading through encapsulation or covalent conjugation. Surface modification enables targeting and reduces toxicity. The architectural precision of dendrimers enables the design of structures tailored to specific therapeutic needs, including gene delivery and antimicrobial applications.¹⁹

5. Micelles and Nanospheres

Micelles are formed by the self-assembly of amphiphilic block copolymers in aqueous solutions. Their core-shell structure enables solubilisation of hydrophobic drugs within the core, while the hydrophilic shell provides steric stability in biological fluids. Polymeric micelles are ideal for solubilising poorly water-soluble drugs and prolonging circulation time.²⁰

Nanospheres are solid matrix systems in which drugs are uniformly dispersed. They offer controlled release and stability advantages, and their synthesis can be adapted to various drug types and therapeutic targets.²¹

6. Exosomes and Biomimetic Carriers

Exosomes are naturally occurring extracellular vesicles derived from cells, playing a crucial role in intercellular communication. Their intrinsic ability to carry proteins, lipids, and RNA, combined with biocompatibility and low immunogenicity, makes them promising drug delivery vehicles. Exosome engineering allows for targeted delivery of therapeutic cargos, and they can be harvested from autologous sources to minimise immune response.²²

Biomimetic carriers, including cell membrane-coated nanoparticles, are designed to mimic natural biological entities. They can evade immune detection, prolong circulation, and achieve specific targeting through surface markers derived from source cells such as red blood cells, platelets, or cancer cells.²³

Figure 1. Classification of Nanocarriers

In conclusion, the classification of nanocarriers reveals a versatile toolkit for overcoming the limitations of traditional drug delivery systems. The continued refinement and hybridisation of these systems promise even more targeted, effective, and safe therapeutic interventions in the future.

Figure 2. Mechanisms of Drug Targeting & Release

In summary, the choice of route of administration for nanocarriers depends on the properties of the drug, the target site, and the clinical goals. Advances in nanotechnology continue to expand the boundaries of what is achievable across all delivery routes, bringing forth a new era of precision therapeutics.

4. Clinical Applications of Nanotechnology in Drug Delivery

Nanotechnology has transitioned from a promising concept to a powerful clinical tool in modern medicine. Its application in drug delivery is now realised across a spectrum of diseases, offering improvements in specificity, efficacy, and patient safety. Several FDA-approved nanomedicines validate their translational success, including Doxil (liposomal doxorubicin), Abraxane (albumin-bound paclitaxel), and Onpattro (patisiran lipid complex).⁴⁶

1. 1. 1. Cancer

Cancer therapy remains the most advanced field in nanomedicine. Nanocarriers address significant challenges in oncology, such as non-specific toxicity, chemoresistance, and the need for combination therapies.

• Passive targeting via the EPR effect enables nanoparticle accumulation in tumour tissues, while active targeting enhances cell-specific uptake through ligands binding to receptors such as HER2, EGFR, or folate.
• Nanocarriers can bypass drug efflux pumps, addressing multidrug resistance.
• Co-delivery systems enable the simultaneous transport of chemotherapeutics with synergistic agents, such as siRNA or immunomodulators.

Doxil reduces cardiotoxicity associated with doxorubicin therapy, while Abraxane enhances the solubility of paclitaxel without relying on toxic solvents. These clinical successes exemplify the promise of nanomedicine in the treatment of cancer.^47,48

1. 1. 2. Neurological Diseases

Neurological disorders are challenging to treat due to the blood-brain barrier (BBB), which limits CNS drug delivery. Nanocarriers, such as liposomes, polymeric nanoparticles, and lipid-based systems, are engineered to cross the blood-brain barrier (BBB) using receptor-mediated transcytosis (e.g., via transferrin or lactoferrin ligands).

• In Alzheimer’s disease, nanoparticles have been used to deliver acetylcholinesterase inhibitors and beta-amyloid-targeting agents.
• In Parkinson’s disease, dopamine or gene therapy agents delivered via nanocarriers bypass systemic metabolism and reach brain regions more effectively.
• For stroke, nanocarriers can encapsulate neuroprotective agents or thrombolytics, delivering them to ischemic regions while minimising systemic effects.^49–51
  1. 3. Infectious Diseases

The global burden of infectious diseases demands novel delivery methods to improve drug efficacy and minimise resistance.

• Nanocarriers protect antimicrobials from degradation, enhance absorption, and enable targeted delivery to infected tissues.
• In tuberculosis (TB), long-acting injectable nanocarriers reduce dosing frequency, improving patient adherence.
• For HIV, nanotechnology has been applied in antiretroviral therapy to improve intracellular uptake and reach latent reservoirs.

Liposomal amphotericin B is a classic example, reducing nephrotoxicity in fungal infections compared to conventional formulations.^52,53

1. 1. 4. Inflammatory and Autoimmune Diseases

Nanocarriers improve the pharmacokinetics of immunomodulatory drugs while reducing systemic toxicity.

• In rheumatoid arthritis, nanoparticles deliver methotrexate or TNF-alpha inhibitors selectively to inflamed joints, enhancing efficacy.
• In inflammatory bowel disease (IBD), pH-sensitive or microbiota-responsive nanocarriers ensure the release of drugs in the colon, thereby bypassing degradation in the upper gastrointestinal tract.
• Surface-modified nanoparticles reduce off-target immune activation, a significant concern with chronic immunosuppressive therapy.

These systems show promise in modulating immune responses without compromising systemic immunity.^54,55

1. 1. 5. Gene Therapy and RNA Delivery

Recent breakthroughs in gene editing and RNA therapeutics rely heavily on nanocarrier technology.

• siRNA and miRNA delivery via lipid nanoparticles allows gene silencing in cancer, viral infections, and genetic disorders.
• mRNA vaccines against COVID-19, using lipid nanoparticles (e.g., Pfizer-BioNTech and Moderna), have demonstrated the scalability and efficacy of this platform.
• CRISPR-Cas9 gene-editing systems require nanocarriers for safe and targeted in vivo delivery, thereby avoiding risks associated with viral vectors.

Onpattro, the first FDA-approved RNAi therapeutic, uses a lipid nanoparticle to deliver siRNA for hereditary transthyretin-mediated amyloidosis, representing a landmark in RNA nanomedicine.^56,57

In summary, nanotechnology-based drug delivery is reshaping clinical paradigms across multiple disciplines, offering tailored therapies that were previously unattainable through conventional means.

5. Safety, Toxicity & Regulatory Issues

As nanotechnology-based drug delivery systems progress from bench to bedside, addressing their safety, toxicity, and regulatory compliance becomes paramount. Despite their therapeutic promise, concerns regarding long-term effects, immune responses, and translation scalability persist and must be rigorously evaluated.⁵⁸

Biocompatibility and Biodegradability

Nanocarriers must be biocompatible to prevent adverse biological reactions. Materials such as phospholipids, PLGA, PEG, and chitosan are generally recognised as safe and have a long history of medical use. Biodegradable carriers are especially favoured as they break down into non-toxic by-products that are easily eliminated from the body. Non-degradable inorganic carriers, such as some metal oxides or quantum dots, require extensive evaluation due to their potential for bioaccumulation and chronic toxicity.⁵⁹

Long-Term Toxicity

Chronic exposure to nanoparticles can lead to tissue accumulation, organ dysfunction, or cytotoxicity. Factors influencing toxicity include size, shape, surface charge, and degradation kinetics. For instance, positively charged nanoparticles may disrupt cell membranes and induce oxidative stress. Longitudinal animal studies and advanced in vitro models are needed to simulate long-term human exposure and provide predictive toxicological data.⁶⁰

Immune Responses

Nanocarriers can elicit immunogenicity or hypersensitivity, potentially leading to adverse effects such as complement activation-related pseudoallergy (CARPA). PEGylation, although widely used to reduce immunogenicity, has been associated with the formation of anti-PEG antibodies in some individuals. Strategies like biomimetic coating or the use of autologous exosomes may mitigate these responses. Immune profiling of patients and preclinical immunotoxicology assessments are crucial to minimise risks.⁶¹

Regulatory Pathways

The regulatory landscape for nanomedicines is evolving. Agencies such as the FDA (U.S.), EMA (Europe), and ICH (International Council for Harmonisation) have issued guidelines emphasising quality, safety, and efficacy.⁶²

• FDA evaluates nanomedicines under existing drug and biologic frameworks, with additional scrutiny for nanospecific issues.
• EMA requires a stepwise approach for nanocarrier characterisation, including physicochemical properties, biodistribution, and safety profiles.
• ICH guidelines, such as Q8–Q10, provide frameworks for pharmaceutical development, risk management, and quality systems that apply to nanomedicines.

Despite these frameworks, a lack of harmonised global standards and validated models for nanotoxicity assessment remains a barrier.^63,64

Challenges in Translation and Scalability

Manufacturing nanomedicines at a clinical or commercial scale while maintaining consistency, stability, and efficacy poses significant hurdles. Batch-to-batch reproducibility, sterilisation, and storage stability are critical factors. Regulatory approval demands comprehensive documentation of manufacturing protocols under Good Manufacturing Practices (GMP).⁶⁵

Moreover, the high costs associated with nanomedicine development and unclear reimbursement policies may hinder commercialisation. Collaborative efforts between academia, industry, and regulatory bodies are essential to bridge these gaps and accelerate clinical translation.⁶⁶

In conclusion, while nanocarriers hold substantial clinical potential, ensuring their safety and meeting regulatory requirements is crucial for their successful integration into healthcare. Continued investment in safety science, standardisation, and regulatory innovation will pave the way for broader acceptance and deployment of nanotechnology in medicine.

6. Current Challenges and Future Prospects

Despite the remarkable progress in nanotechnology-based drug delivery, several critical challenges continue to impede its full-scale translation and integration into mainstream healthcare. These obstacles span technical, regulatory, and systemic domains, but ongoing innovations and interdisciplinary approaches hold promise for overcoming them.⁶⁷

Scale-Up and Reproducibility Issues

One of the most significant barriers to clinical adoption is the difficulty in scaling up laboratory-developed nanocarriers to industrial production levels while maintaining batch-to-batch reproducibility. The complex synthesis and functionalisation processes required for many nanocarriers introduce variability in size, surface charge, drug loading, and stability. Minor inconsistencies can drastically impact therapeutic performance and safety.⁶⁸

To address this, there is a growing emphasis on developing standardised, automated, and modular manufacturing platforms. Microfluidic technologies and continuous-flow synthesis offer promising avenues for precision and reproducibility. Moreover, advanced analytical tools like dynamic light scattering (DLS), nanoparticle tracking analysis (NTA), and high-resolution electron microscopy are essential for rigorous quality control during scale-up.⁶⁹

Regulatory Bottlenecks

The regulatory environment for nanomedicines is still maturing. Existing frameworks, initially designed for conventional small-molecule drugs or biologics, often fall short in addressing the unique properties of nanocarriers. Regulatory ambiguity creates delays in approval and increases the cost of bringing nanodrugs to market.⁷⁰

Harmonisation of international standards, development of validated toxicity assays, and early engagement with regulatory bodies are critical to navigating these challenges. Regulatory science must evolve in parallel with nanotechnology to ensure both innovation and patient safety.⁷¹

Personalised and AI-Driven Nanomedicine

Precision medicine calls for therapies tailored to individual genetic, phenotypic, and environmental profiles. Nanotechnology, with its capacity for functional customisation, is ideally suited to fulfil this vision. Personalised nanocarriers can be engineered based on patient-specific biomarkers, enhancing targeting and reducing adverse effects.⁷²

Artificial Intelligence (AI) and machine learning (ML) are being increasingly integrated into nanomedicine for the predictive modelling of drug release, biodistribution, and therapeutic outcomes. AI can also optimise formulation parameters, identify lead candidates, and accelerate preclinical development by analysing complex datasets.^73,74

Green Nanotechnology and Sustainable Development

As the environmental impact of nanomaterial production becomes more apparent, green nanotechnology has emerged as a vital area of focus. It involves the design and synthesis of nanocarriers using eco-friendly materials and energy-efficient processes. Biogenic synthesis using plant extracts or microorganisms, solvent-free processing, and biodegradable polymers contribute to reduced ecological footprints.⁷⁵

Sustainable development in nanomedicine encompasses not only waste management and lifecycle analysis but also equitable access. Ensuring that advanced therapeutics do not exacerbate health disparities or environmental degradation is essential for long-term viability.⁷⁶

Integration with Bioinformatics and Predictive Modelling

The convergence of nanotechnology with bioinformatics offers powerful tools for drug development and therapeutic optimisation. Predictive modelling platforms can simulate nanoparticle interactions with biological systems, forecast pharmacokinetic behaviour, and identify optimal design parameters. Omics technologies (genomics, proteomics, metabolomics) feed data into these models, enabling rational design of nanocarriers for complex diseases. This integrative approach minimises trial-and-error experimentation, reduces development costs, and enhances translational success rates.⁷⁷

The future of nanotechnology in drug delivery lies at the intersection of multidisciplinary innovation, regulatory reform, and sustainability. Addressing current challenges in manufacturing, regulation, and personalisation through emerging technologies and systems biology will unlock the full potential of nanomedicine. As the field advances, its impact on patient-specific, environmentally responsible, and clinically transformative therapies will continue to grow.⁷⁸

CONCLUSION

Nanotechnology has revolutionised the landscape of drug delivery by addressing the critical shortcomings of conventional therapeutic modalities. Through the design of advanced nanocarriers, ranging from liposomes and polymeric nanoparticles to exosomes and dendrimers, researchers have developed systems capable of targeted delivery, controlled release, and traversal of biological barriers. These technologies have demonstrated profound clinical potential, particularly in the management of cancer, neurological disorders, infectious diseases, and genetic conditions.

A key strength of nanotechnology lies in its capacity for customisation. Functionalisation strategies enable selective targeting of pathological sites, while stimuli-responsive mechanisms provide controlled and site-specific drug release. The translation of these concepts into real-world therapeutics is evidenced by several FDA-approved nanodrugs, such as Doxil, Abraxane, and Onpattro, which have improved treatment outcomes and minimised toxicity.

However, the full potential of nanomedicine will only be realised through robust interdisciplinary collaboration. Advances in materials science, bioengineering, pharmacology, and computational modelling must be harmonised to overcome challenges in scale-up, regulatory approval, and long-term safety evaluation. Furthermore, the integration of artificial intelligence, bioinformatics, and green chemistry will be pivotal in driving the next generation of sustainable and personalised nanomedicines.

Looking ahead, nanotechnology is poised to redefine how drugs are developed, delivered, and optimised. Its convergence with emerging technologies and its adaptability to patient-specific profiles position it as a cornerstone of future precision healthcare. As research matures and regulatory pathways evolve, nanomedicine holds the promise of more effective, safer, and accessible therapies that will significantly impact global health outcomes.

Conflict of interest: The authors declare no conflict of interest.

REFERENCES

1. Haleem A, Javaid M, Singh RP, et al. Applications of nanotechnology in medical field: a brief review. Global Health Journal 2023;7(2):70–77; doi: 10.1016/j.glohj.2023.02.008.
2. Irvine DJ, Dane EL. Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol 2020;20(5):321–334; doi: 10.1038/s41577-019-0269-6.
3. Cheng X, Xie Q, Sun Y. Advances in nanomaterial-based targeted drug delivery systems. Front Bioeng Biotechnol 2023;11:1177151; doi: 10.3389/fbioe.2023.1177151.
4. Fan Q, He Z, Xiong J, et al. Smart Drug Delivery Systems Based on DNA Nanotechnology. ChemPlusChem 2022;87(3):e202100548; doi: 10.1002/cplu.202100548.
5. Peer D, Karp JM, Hong S, et al. Nanocarriers as an Emerging Platform for Cancer Therapy. In: Nano-Enabled Medical Applications. (Balogh LP. ed) Jenny Stanford Publishing; 2020; pp. 61–91; doi: 10.1201/9780429399039-2.
6. Mi P. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. Theranostics 2020;10(10):4557–4588; doi: 10.7150/thno.38069.
7. Khizar S, Alrushaid N, Alam Khan F, et al. Nanocarriers based novel and effective drug delivery system. International Journal of Pharmaceutics 2023;632:122570; doi: 10.1016/j.ijpharm.2022.122570.
8. Wakaskar RR. General overview of lipid–polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes. Journal of Drug Targeting 2018;26(4):311–318; doi: 10.1080/1061186X.2017.1367006.
9. Liu P, Chen G, Zhang J. A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules 2022;27(4):1372; doi: 10.3390/molecules27041372.
10. Paliwal R, Paliwal SR, Kenwat R, et al. Solid lipid nanoparticles: a review on recent perspectives and patents. Expert Opinion on Therapeutic Patents 2020;30(3):179–194; doi: 10.1080/13543776.2020.1720649.
11. Chauhan I, Yasir M, Verma M, et al. Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery. Adv Pharm Bull 2020;10(2):150–165; doi: 10.34172/apb.2020.021.
12. Xiao L, Xu W, Huang L, et al. Nanocomposite pastes of gelatin and cyclodextrin-grafted chitosan nanoparticles as potential postoperative tumor therapy. Adv Compos Hybrid Mater 2023;6(1):15; doi: 10.1007/s42114-022-00575-3.
13. Lehner E, Liebau A, Menzel M, et al. Characterization of PLGA versus PEG-PLGA intracochlear drug delivery implants: Degradation kinetics, morphological changes, and pH alterations. Journal of Drug Delivery Science and Technology 2024;99:105972; doi: 10.1016/j.jddst.2024.105972.
14. Siddique S, Chow JCL. Gold Nanoparticles for Drug Delivery and Cancer Therapy. Applied Sciences 2020;10(11):3824; doi: 10.3390/app10113824.
15. Manzano M, Vallet‐Regí M. Mesoporous Silica Nanoparticles for Drug Delivery. Adv Funct Materials 2020;30(2):1902634; doi: 10.1002/adfm.201902634.
16. Dulińska-Litewka J, Łazarczyk A, Hałubiec P, et al. Superparamagnetic Iron Oxide Nanoparticles—Current and Prospective Medical Applications. Materials 2019;12(4):617; doi: 10.3390/ma12040617.
17. Nair A, Haponiuk JT, Thomas S, et al. Natural carbon-based quantum dots and their applications in drug delivery: A review. Biomedicine & Pharmacotherapy 2020;132:110834; doi: 10.1016/j.biopha.2020.110834.
18. Pérez-Ferreiro M, M. Abelairas A, Criado A, et al. Dendrimers: Exploring Their Wide Structural Variety and Applications. Polymers 2023;15(22):4369; doi: 10.3390/polym15224369.
19. Kasprzak A, Dabrowski B, Zuchowska A. A biocompatible poly(amidoamine) (PAMAM) dendrimer octa-substituted with α-cyclodextrin towards the controlled release of doxorubicin hydrochloride from its ferrocenyl prodrug. RSC Adv 2020;10(39):23440–23445; doi: 10.1039/D0RA03694C.
20. Hussein YHA, Youssry M. Polymeric Micelles of Biodegradable Diblock Copolymers: Enhanced Encapsulation of Hydrophobic Drugs. Materials 2018;11(5):688; doi: 10.3390/ma11050688.
21. Geyik G, Işıklan N. Design and fabrication of hybrid triple-responsive κ-carrageenan-based nanospheres for controlled drug delivery. International Journal of Biological Macromolecules 2021;192:701–715; doi: 10.1016/j.ijbiomac.2021.10.007.
22. Dilsiz N. Exosomes as new generation vehicles for drug delivery systems. Journal of Drug Delivery Science and Technology 2024;95:105562; doi: 10.1016/j.jddst.2024.105562.
23. Li A, Zhao Y, Li Y, et al. Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles. Drug Delivery 2021;28(1):1237–1255; doi: 10.1080/10717544.2021.1938757.
24. Chamundeeswari M, Jeslin J, Verma ML. Nanocarriers for drug delivery applications. Environ Chem Lett 2019;17(2):849–865; doi: 10.1007/s10311-018-00841-1.
25. Kalyane D, Raval N, Maheshwari R, et al. Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Materials Science and Engineering: C 2019;98:1252–1276; doi: 10.1016/j.msec.2019.01.066.
26. Biffi S, Voltan R, Bortot B, et al. Actively targeted nanocarriers for drug delivery to cancer cells. Expert Opinion on Drug Delivery 2019;16(5):481–496; doi: 10.1080/17425247.2019.1604679.
27. Sun T, Jiang C. Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments. Advanced Drug Delivery Reviews 2023;196:114773; doi: 10.1016/j.addr.2023.114773.
28. Tian B, Liu Y, Liu J. Smart stimuli-responsive drug delivery systems based on cyclodextrin: A review. Carbohydrate Polymers 2021;251:116871; doi: 10.1016/j.carbpol.2020.116871.
29. Kashani GK, Naghib SM, Soleymani S, et al. A review of DNA nanoparticles-encapsulated drug/gene/protein for advanced controlled drug release: Current status and future perspective over emerging therapy approaches. International Journal of Biological Macromolecules 2024;268:131694; doi: 10.1016/j.ijbiomac.2024.131694.
30. Duncan R, Richardson SCW. Endocytosis and Intracellular Trafficking as Gateways for Nanomedicine Delivery: Opportunities and Challenges. Mol Pharmaceutics 2012;9(9):2380–2402; doi: 10.1021/mp300293n.
31. Hughes KA, Misra B, Maghareh M, et al. Use of stimulatory responsive soft nanoparticles for intracellular drug delivery. Nano Res 2023;16(5):6974–6990; doi: 10.1007/s12274-022-5267-5.
32. Chenthamara D, Subramaniam S, Ramakrishnan SG, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res 2019;23(1):20; doi: 10.1186/s40824-019-0166-x.
33. Haddadzadegan S, Dorkoosh F, Bernkop-Schnürch A. Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers. Advanced Drug Delivery Reviews 2022;182:114097; doi: 10.1016/j.addr.2021.114097.
34. Tarfaoui M, Lafdi K, Beloufa I, et al. Effect of Graphene Nano-Additives on the Local Mechanical Behavior of Derived Polymer Nanocomposites. Polymers 2018;10(6):667; doi: 10.3390/polym10060667.
35. Qin J, Zeng S, Wang X, et al. Generation of micro(nano)plastics and migration of plastic additives from Poly(vinyl chloride) in water under radiation-free ambient conditions. Chemosphere 2022;299:134399; doi: 10.1016/j.chemosphere.2022.134399.
36. Pache MM, Thorat AS, Mule RR, et al. RECENT ADVANCES IN THE USE OF ALKALOIDS AS THERAPEUTIC AGENTS: A PHARMACOGNOSTIC PERSPECTIVE. World Journal of Pharmaceutical Research 2025;14(2):538–552.
37. Czerniel J, Gostyńska A, Jańczak J, et al. A critical review of the novelties in the development of intravenous nanoemulsions. European Journal of Pharmaceutics and Biopharmaceutics 2023;191:36–56; doi: 10.1016/j.ejpb.2023.08.009.
38. Camacho Vieira C, Peltonen L, Karttunen AP, et al. Is it advantageous to use quality by design (QbD) to develop nanoparticle-based dosage forms for parenteral drug administration? International Journal of Pharmaceutics 2024;657:124163; doi: 10.1016/j.ijpharm.2024.124163.
39. Fecioru E, Klein M, Krämer J, et al. In Vitro Performance Testing of Nanoparticulate Drug Products for Parenteral Administration. Dissolution Technol 2019;26(3):28–37; doi: 10.14227/DT260319P28.
40. Desai JL, Pandya T, Patel A. Nanocarriers in Transdermal Drug Delivery. In: Nanocarriers: Drug Delivery System. (Shah N. ed) Springer Singapore: Singapore; 2021; pp. 383–409; doi: 10.1007/978-981-33-4497-6_16.
41. M. M. . Pache, R. R. . . Pangavhane, T. V. . Kadam, V. R. . Chavan, and A. B. . Darekar, “Curcumin-Loaded Nanoemulsions: Advances in Formulation Strategies and Anti-Inflammatory Therapeutic Applications”, J. Drug Delivery Ther., vol. 16, no. 1, pp. 146–158, Jan. 2026, doi: 10.22270/jddt.v16i1.7507.
42. Omidian H, Wilson RL. PLGA-Based Strategies for Intranasal and Pulmonary Applications. Pharmaceutics 2025;17(2):207; doi: 10.3390/pharmaceutics17020207.
43. Heida R, Frijlink HW, Hinrichs WLJ. Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration. Palese P. ed. mBio 2023;14(5):e01295-23; doi: 10.1128/mbio.01295-23.
44. Das B, Nayak AK, Mallick S. Lipid-based nanocarriers for ocular drug delivery: An updated review. Journal of Drug Delivery Science and Technology 2022;76:103780; doi: 10.1016/j.jddst.2022.103780.
45. Teixeira MI, Lopes CM, Amaral MH, et al. Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): A current overview of active targeting in brain diseases. Colloids and Surfaces B: Biointerfaces 2023;221:112999; doi: 10.1016/j.colsurfb.2022.112999.
46. Sahu T, Ratre YK, Chauhan S, et al. Nanotechnology based drug delivery system: Current strategies and emerging therapeutic potential for medical science. Journal of Drug Delivery Science and Technology 2021;63:102487; doi: 10.1016/j.jddst.2021.102487.
47. Xu M, Han X, Xiong H, et al. Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials. Molecules 2023;28(13):5145; doi: 10.3390/molecules28135145.
48. Fan D, Cao Y, Cao M, et al. Nanomedicine in cancer therapy. Sig Transduct Target Ther 2023;8(1):293; doi: 10.1038/s41392-023-01536-y.
49. Teixeira MI, Lopes CM, Amaral MH, et al. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. European Journal of Pharmaceutics and Biopharmaceutics 2020;149:192–217; doi: 10.1016/j.ejpb.2020.01.005.
50. Ashique S, Afzal O, Yasmin S, et al. Strategic nanocarriers to control neurodegenerative disorders: Concept, challenges, and future perspective. International Journal of Pharmaceutics 2023;633:122614; doi: 10.1016/j.ijpharm.2023.122614.
51. Pache M, Kedar H, Kond S, et al. Pharmacological Management of Neurodegenerative Disorders: Current and Future Approaches. Int J Sci R Tech 2025;2(3):405–520; doi: 10.5281/ZENODO.15074000.
52. Kirtane AR, Verma M, Karandikar P, et al. Nanotechnology approaches for global infectious diseases. Nat Nanotechnol 2021;16(4):369–384; doi: 10.1038/s41565-021-00866-8.
53. Pache M, Nikam S. Antibiotic Resistance: Current Challenges and Future Directions. Int J of Pharm Sci 2025;3(1):1600–1622; doi: 10.5281/ZENODO.14690670.
54. Talamini L, Matsuura E, De Cola L, et al. Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases. Cells 2021;10(3):707; doi: 10.3390/cells10030707.
55. Pache MM, Pangavhane RR. Immunotherapy in Autoimmune Diseases: Current Advances and Future Directions. Asian Journal of Pharmaceutical Research 2025.
56. Zhu L, Luo J, Ren K. Nucleic acid-based artificial nanocarriers for gene therapy. J Mater Chem B 2023;11(2):261–279; doi: 10.1039/D2TB01179D.
57. Zhang J, Yang X, Chang Z, et al. Polymeric nanocarriers for therapeutic gene delivery. Asian Journal of Pharmaceutical Sciences 2025;20(1):101015; doi: 10.1016/j.ajps.2025.101015.
58. Patnaik S, Gorain B, Padhi S, et al. Recent update of toxicity aspects of nanoparticulate systems for drug delivery. European Journal of Pharmaceutics and Biopharmaceutics 2021;161:100–119; doi: 10.1016/j.ejpb.2021.02.010.
59. Kiew SF, Kiew LV, Lee HB, et al. Assessing biocompatibility of graphene oxide-based nanocarriers: A review. Journal of Controlled Release 2016;226:217–228; doi: 10.1016/j.jconrel.2016.02.015.
60. Yang W, Wang L, Mettenbrink EM, et al. Nanoparticle Toxicology. Annu Rev Pharmacol Toxicol 2021;61(1):269–289; doi: 10.1146/annurev-pharmtox-032320-110338.
61. Li L, Yan X, Xia M, et al. Nanoparticle/Nanocarrier Formulation as an Antigen: The Immunogenicity and Antigenicity of Itself. Mol Pharmaceutics 2022;19(1):148–159; doi: 10.1021/acs.molpharmaceut.1c00704.
62. Foulkes R, Man E, Thind J, et al. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives. Biomater Sci 2020;8(17):4653–4664; doi: 10.1039/D0BM00558D.
63. Csóka I, Ismail R, Jójárt-Laczkovich O, et al. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development. CMC 2021;28(36):7461–7476; doi: 10.2174/0929867328666210406115529.
64. Ali F, Neha K, Parveen S. Current regulatory landscape of nanomaterials and nanomedicines: A global perspective. Journal of Drug Delivery Science and Technology 2023;80:104118; doi: 10.1016/j.jddst.2022.104118.
65. Operti MC, Bernhardt A, Grimm S, et al. PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up. International Journal of Pharmaceutics 2021;605:120807; doi: 10.1016/j.ijpharm.2021.120807.
66. Zhang C, Yan L, Wang X, et al. Progress, challenges, and future of nanomedicine. Nano Today 2020;35:101008; doi: 10.1016/j.nantod.2020.101008.
67. Wen MM, El-Salamouni NS, El-Refaie WM, et al. Nanotechnology-based drug delivery systems for Alzheimer’s disease management: Technical, industrial, and clinical challenges. Journal of Controlled Release 2017;245:95–107; doi: 10.1016/j.jconrel.2016.11.025.
68. Khairnar SV, Pagare P, Thakre A, et al. Review on the Scale-Up Methods for the Preparation of Solid Lipid Nanoparticles. Pharmaceutics 2022;14(9):1886; doi: 10.3390/pharmaceutics14091886.
69. Gimondi S, Ferreira H, Reis RL, et al. Microfluidic Devices: A Tool for Nanoparticle Synthesis and Performance Evaluation. ACS Nano 2023;17(15):14205–14228; doi: 10.1021/acsnano.3c01117.
70. Foulkes R, Man E, Thind J, et al. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives. Biomater Sci 2020;8(17):4653–4664; doi: 10.1039/D0BM00558D.
71. Halamoda-Kenzaoui B, Geertsma R, Pouw J, et al. Future perspectives for advancing regulatory science of nanotechnology-enabled health products. Drug Deliv and Transl Res 2022;12(9):2145–2156; doi: 10.1007/s13346-022-01165-y.
72. Ren J, Cai R, Wang J, et al. Precision Nanomedicine Development Based on Specific Opsonization of Human Cancer Patient-Personalized Protein Coronas. Nano Lett 2019;19(7):4692–4701; doi: 10.1021/acs.nanolett.9b01774.
73. Chen C, Yaari Z, Apfelbaum E, et al. Merging data curation and machine learning to improve nanomedicines. Advanced Drug Delivery Reviews 2022;183:114172; doi: 10.1016/j.addr.2022.114172.
74. Pache MM, Pangavhane RR, Jagtap MN, et al. The AI-Driven Future of Drug Discovery: Innovations, Applications, and Challenges. Asian J Res Pharm Sci 2025;15(1):61–67; doi: 10.52711/2231-5659.2025.00009.